In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO.

Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.

Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find.

In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone.

Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape.

The MHRA’s spring 2026 CE-marking consultation, the progress of UK medtech statutory instruments and the European Commission’s proposed revision of the MDR and IVDR were top of mind for the Association of British HealthTech Industries' Steve Lee as he did the rounds – and the panels – at the MedTech Forum 2026.